Summit Therapeutics (SMMT) P/S ratio

P/S ratio · fiscal 2021
195.9×

The P/S ratio of Summit Therapeutics (SMMT) was 195.9× at the end of fiscal 2021 (December 31, 2021). That is 48.5% lower than the 380.0× of fiscal 2020. Figures as of 18 Nov 2026, 07:30 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio, fiscal 2021
195.9×
Change on fiscal 2020
−48.5%
Highest on record
380.0×fiscal 2020
Lowest on record
0.4×fiscal 2019
Fiscal years on record
32019–2021

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Summit Therapeutics P/S ratio, in more detail

Across the 3 fiscal year-ends on record (2019–2021), the highest was 380.0× in fiscal 2020 and the lowest 0.4× in fiscal 2019.

History · 3 fiscal years

P/S ratio at each fiscal year-end

Summit Therapeutics P/S ratio, year by year

Summit Therapeutics (SMMT) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
2025——$17.49—
2024——$17.84—
2023——$2.61—
2022——$4.25$0.00
2021195.9× 48.5% down$2.69$0.01
2020380.0× 94,561.9% up$4.70$0.01
20190.4×—$1.33$3.31

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Summit Therapeutics and comparable companies
CompanyP/S ratio
BridgeBio Pharma BBIO29.8×
Glaukos GKOS28.4×
Encompass Health EHC2.3×
BrightSpring Health Services BTSG1.1×
Baxter International BAX1.2×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on SMMT

Summit Therapeutics, figure by figure

Summit Therapeutics (SMMT) overview: price, valuation and scorecardAll health care companies by market value

Summit Therapeutics P/S ratio: questions and answers

What is Summit Therapeutics's P/S ratio?

The P/S ratio of Summit Therapeutics (SMMT) was 195.9× at the end of fiscal 2021 (December 31, 2021). That is 48.5% lower than the 380.0× of fiscal 2020.

What are the highest and lowest P/S ratio figures on record for Summit Therapeutics?

Across the 3 fiscal year-ends on record (2019–2021), the highest was 380.0× in fiscal 2020 and the lowest 0.4× in fiscal 2019.

How is Summit Therapeutics's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Summit Therapeutics (SMMT) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/SMMT/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.